Ray Stevens, Structure Therapeutics CEO
Structure in partnering talks for GLP-1 pill as mid-stage readout nears
It is a truth universally acknowledged that a biotech in possession of a mid-stage GLP-1 must be in want of a partner. Structure Therapeutics is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
